Baader Bank Aktiengesellschaft Acquires 7,630 Shares of Zoetis Inc. $ZTS

Baader Bank Aktiengesellschaft raised its position in shares of Zoetis Inc. (NYSE:ZTS) by 28.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 34,464 shares of the company’s stock after acquiring an additional 7,630 shares during the period. Baader Bank Aktiengesellschaft’s holdings in Zoetis were worth $4,273,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of ZTS. RFG Advisory LLC lifted its stake in shares of Zoetis by 4.9% in the fourth quarter. RFG Advisory LLC now owns 1,708 shares of the company’s stock valued at $215,000 after buying an additional 80 shares during the period. YANKCOM Partnership raised its position in Zoetis by 3.5% in the fourth quarter. YANKCOM Partnership now owns 2,402 shares of the company’s stock worth $302,000 after purchasing an additional 81 shares in the last quarter. Evergreen Capital Management LLC increased its holdings in shares of Zoetis by 3.3% during the third quarter. Evergreen Capital Management LLC now owns 2,696 shares of the company’s stock worth $394,000 after buying an additional 85 shares in the last quarter. Beese Fulmer Investment Management Inc. increased its holdings in shares of Zoetis by 2.4% during the third quarter. Beese Fulmer Investment Management Inc. now owns 3,672 shares of the company’s stock worth $537,000 after buying an additional 85 shares in the last quarter. Finally, Quest 10 Wealth Builders Inc. increased its holdings in shares of Zoetis by 4.7% in the fourth quarter. Quest 10 Wealth Builders Inc. now owns 1,904 shares of the company’s stock valued at $240,000 after purchasing an additional 86 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages recently weighed in on ZTS. JPMorgan Chase & Co. lowered their price target on shares of Zoetis from $190.00 to $130.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Weiss Ratings cut shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, March 27th. Citigroup started coverage on shares of Zoetis in a research report on Wednesday, April 15th. They issued a “buy” rating and a $145.00 price objective on the stock. William Blair reaffirmed an “outperform” rating on shares of Zoetis in a research report on Monday, March 2nd. Finally, Leerink Partners reiterated a “market perform” rating on shares of Zoetis in a research note on Tuesday, March 10th. Seven equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $141.25.

Insider Buying and Selling at Zoetis

In other Zoetis news, Director Frank A. Damelio acquired 6,650 shares of the business’s stock in a transaction on Wednesday, May 13th. The stock was purchased at an average price of $75.39 per share, with a total value of $501,343.50. Following the acquisition, the director directly owned 21,458 shares of the company’s stock, valued at approximately $1,617,718.62. This trade represents a 44.91% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Paul Bisaro purchased 2,000 shares of the business’s stock in a transaction dated Wednesday, May 13th. The shares were purchased at an average cost of $75.88 per share, with a total value of $151,760.00. Following the acquisition, the director owned 27,862 shares in the company, valued at $2,114,168.56. This trade represents a 7.73% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders acquired 11,650 shares of company stock valued at $886,384 in the last quarter. Company insiders own 0.22% of the company’s stock.

Zoetis Stock Performance

Shares of ZTS stock opened at $74.32 on Thursday. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15. The company has a market capitalization of $31.16 billion, a price-to-earnings ratio of 12.33, a PEG ratio of 1.26 and a beta of 0.87. Zoetis Inc. has a 52 week low of $74.29 and a 52 week high of $172.23. The company has a 50-day simple moving average of $114.33 and a 200 day simple moving average of $121.77.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The business had revenue of $2.26 billion during the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The business’s revenue for the quarter was up 2.9% on a year-over-year basis. During the same period in the prior year, the firm earned $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, sell-side analysts predict that Zoetis Inc. will post 6.89 earnings per share for the current year.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.